Table 3. Univariate analysis for relapse-free and overall survival.
| Characteristics | Risk of relapse or death | Risk of death | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age, years | 1.01 | 1.00-1.03 | 0.10 | 1.02 | 1.01-1.04 | 0.01 |
| Log WBC | 1.06 | 0.70-1.60 | 0.77 | 1.07 | 0.62-1.40 | 0.72 |
| Platelets | 1.00 | 0.99-1.00 | 0.24 | 1.00 | 1.00-1.00 | 0.37 |
| BM blast (%) | 1.02 | 1.00-1.03 | 0.13 | 1.02 | 1.00-1.04 | 0.09 |
| Performance status ≥2 | 2.15 | 1.02-4.56 | 0.05 | 2.20 | 1.07-4.50 | 0.03 |
| CD20 expression ≥20% | 1.29 | 0.77-2.18 | 0.36 | 1.54 | 0.91-2.63 | 0.11 |
| CNS leukemia | 1.21 | 0.60-2.47 | 0.59 | 1.60 | 0.83-3.09 | 0.16 |
| p190 BCR-ABL1 transcript | 0.67 | 0.37-1.22 | 0.19 | 0.57 | 0.30-1.07 | 0.08 |
| TKI: ponatinib vs. dasatinib vs. imatinib | 0.68 | 0.47-0.99 | 0.04 | 0.61 | 0.42-0.89 | 0.01 |
| Poor-risk ACAs | 2.16 | 1.19-3.94 | 0.01 | 2.35 | 1.32-4.17 | 0.003 |
HR, hazard ratio; CI, confidence interval; WBC, white blood cell; BM, bone marrow; CNS, central nervous system; TKI, tyrosine kinase inhibitor; ACAs, additional chromosomal abnormalities